Globally, antidepressant usage has been on the rise. As of 2023, among select Organization for Economic Cooperation and Development (OECD) countries, Iceland, Portugal, and the UK were the biggest consumers of antidepressants. At that time, people in Iceland consumed antidepressants at a rate of about *** defined daily doses (DDD) per 1,000 people. Mental health globally Mental health disorders affect a significant proportion of the population, though addressing and understanding the prevalence of mental health is difficult due to regional differences in diagnostic criteria and understandings of mental health. Despite barriers to gathering data on mental health, there have been some global quantitative studies to help better understand certain conditions. It is suggested that mental health is among the top three health concerns among adults worldwide. Estimates propose that about ** percent of the overall population suffers from some mental health or substance use disorder. Depression and anxiety A global survey showed that the largest numbers of people with anxiety resided in locations in South-East Asia and the Americas. However, the highest distribution of cases of depression globally is among populations in South-East Asia and the Western Pacific. Both depression and anxiety disproportionately impact women in all regions of the world.

Across the analyzed European countries, the consumption of antidepressant drugs between 2010 and 2020 showed, for all countries except Denmark, an increasing trend. Estonia recorded the highest increase in consumption, with *** percent. Latvia and the UK followed, with an increase of *** and *** percent, respectively. Conversely, Denmark was the only country from this group which showed a reduction in the use of antidepressants. This statistics depicts the percentage change in consumption of antidepressant drugs between 2010 and 2020 in Europe, by country.

Based on pharmacy claims of those who filled at least one prescription for mental health medication in 2019, antidepressant use is most prevalent in West Virginia, Kentucky, Vermont, and New Hampshire. This statistic shows the percentage of patients (excluding those on government-sponsored benefits) who filled a prescription for antidepressants in the U.S. in 2019, by state.

Data from Wigmore et al 'Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP'. The Pharmacogenomics Journal 20, 329-341 (2020) DOI:10.1038/s41397-019-0067-3 This dataset consists of two sets of GWAS summary statistics: - case-control analysis of treatment resistance phenotype in the Generation Scotland and GENDEP samples (inverse variance weighted meta-analysis). Cases = 358, Controls = 3855. - quantitative stages of resistance phenotype in Generation Scotland. N = 3452.

According to the European health survey, over 11 percent of women older than 65 years consumed antidepressants or stimulants in Spain in 2020. On the other hand, only 3.57 percent of men of that same age used antidepressants or stimulants. The lowest percentage was found in respondents between the ages of 15 and 24 for both genders.

From February 24 to March 1, 2020, the volume of antidepressants sold in Russia was **** percent higher than in the corresponding week of the previous year. The sales value growth was measured at ** percent over the same week.

The Global Bipolar Disorder Therapeutics market is expected to grow above a CAGR of 2.0% and is anticipated to reach over USD 4,384.2 Million by 2026.

This study aimed to examine the association between change in social evaluation learning and mood over the first eight weeks of antidepressant treatment. Participants were primary care patients receiving antidepressant treatment under the care of their GP. Participants completed data collection at five timepoints; baseline (prior to starting antidepressants or within the first two weeks of treatment), two week, six week, eight week and six-month follow-up. At each testing session participants completed self-report measures of depression (BDI-II, PHQ-9), anxiety (GAD-7), and a computerised task measuring learning of social evaluations about the self, a friend and a stranger.

Prior to the COVID-19 pandemic participants also completed three other cognitive tasks (associative learning, word categorisation and recall, and a facial emotion recognition task). To reduce fatigue effects associated with remote testing we removed these tasks from March 2020. Due to only a small number of participants completing these measures we have not analysed this data and have therefore not reported results in the associated paper. However, we have made the data open access to allow for exploratory research in preparation for potential future studies. Full details of these tasks are available in supplementary materials in the manuscript reporting our main findings.

Serotonin reuptake inhibitor (SRI) antidepressants are implicated in increasing the risk of bleeding among users; however, the comparative increase in bleeding risk with concurrent antithrombotic therapy (anticoagulant or antiplatelet) remains unclear. As such, we performed a systematic review and meta-analysis of all available evidence to evaluate the effects of SRI and the risk of bleeding complications among patients receiving antithrombotic therapy. We searched Medline, Embase, PubMed, PsycINFO, Cochrane Library, Web of Science, Scopus, CINAHL, and grey literature (Google Scholar and preprint reports) up to 26 November, 2020, with no language restrictions (updated on 31 July 2021). The primary outcome of interest was major bleeding. Secondary outcomes included intracranial haemorrhage, gastrointestinal bleeding, and any bleeding events. We used a random-effects model meta-analysis to estimate the odds ratios (ORs) and 95% confidence intervals (CIs). We did not identify any randomised studies but found 32 non-randomized studies (cohort or case–control) with 1,848,285 patients that fulfilled the study selection criteria and were included in the meta-analysis. Among individuals receiving anticoagulants (13 studies), SRI users experienced a statistically higher risk of major bleeding compared to non-SRI users: pooled OR was 1.39 (95% CI, 1.23–1.58; p 

The usage rate of antidepressants in Norway in 2020 increased constantly with each higher age group, with an exception of persons aged 90 years and older. The use was highest in the group of persons aged between 85 and 89 years, with some 133 users per thousand inhabitants.

IntroductionHypnotic polypharmacy and its long-term prescriptions constitute the inappropriate use of hypnotics. However, the relationship between hypnotic polypharmacy and prolonged prescriptions remains unclear. This study aimed to elucidate the association between hypnotic polypharmacy and the duration of hypnotic prescriptions.MethodsThis retrospective, cross-sectional study utilized a large dataset from the Japan Medical Data Center. The study population included adults who had been prescribed hypnotics between April 2020 and March 2021, with a focus on those receiving hypnotics in March 2021. Hypnotic polypharmacy was defined as the concurrent prescription of two or more hypnotics in March 2021. The duration of hypnotic prescriptions was measured by calculating the number of months between April 2019 and March 2021 during which hypnotics were prescribed. A binary logistic regression analysis was conducted to assess the relationship between hypnotic polypharmacy and long-term hypnotic prescriptions, adjusting for relevant covariates.ResultsWe included 112,256 patients (mean age: 49.5 years, females: 47.1%). Among them, 67.9% received hypnotic monotherapy, and 32.1% received hypnotic polypharmacy. Compared with adults who were prescribed hypnotics for 1 month, the association with polypharmacy was stronger in those who were prescribed hypnotics for ≥4 months as the duration of the prescription increased (adjusted odds ratio [aOR]: 1.15, 95% confidence interval [CI]: 1.04–1.27, p=0.006 for 4–6 months; aOR 1.35, 95% CI 1.23–1.49, p

The number of users of antidepressants in Denmark fluctuated slightly, but was relatively stable during the whole period from second quarter of 2017 to the second quarter of 2020. There were around 294.3 thousand users of antidepressants in Denmark during the second quarter of 2020.

Le marché mondial des thérapies contre les troubles bipolaires devrait croître à un TCAC de plus de 2.0 % et devrait atteindre plus de 4,384.2 2026 millions USD d'ici XNUMX.

Der globale Markt für Therapeutika für bipolare Störungen wird voraussichtlich mit einer durchschnittlichen jährlichen Wachstumsrate von über 2.0 % wachsen und bis 4,384.2 einen Wert von über 2026 Millionen US-Dollar erreichen.

Between March and April 2020, Poles spent 24 percent more on sedatives and sleeping pills than a year before and 33 percent more on antidepressants. According to the source, Poles spent a total of over 200 million zloty between March and April 2020 on this purpose.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

In 2020, non qualified female workers had the highest consumption of antidepressants or stimulants in Spain with around ***** percent of respondents. In the case of men, *** percent of non-qualified workers consumed this type of medication.

Across the analyzed European countries, the consumption of antidepressant drugs between 2000 and 2020 showed, for all countries, an increasing trend. Portugal recorded the highest increase in consumption, from 32 to 131 DDD per 1,000 people per day. This statistic shows the consumption of antidepressant drugs in France, Germany, Portugal, Spain, and Sweden, between 2000 and 2020.

By 2018, over ***** percent of the Belgian population were consuming antidepressants drugs. In addition, the daily dosage of antidepressants increased in Belgium. Indeed, the defined daily dosage per 1,000 inhabitants per day of antidepressants rose from **** in 2005 to ** in 2017. Ultimately, Belgians were consuming more antidepressants than ever before.

In 2020, *** out of five Belgians suffers from an anxiety disorder 

The rise of antidepressant use supports the increasing prevalence of depressive and generalized anxiety disorders among the Belgian population. In early 2020, it was estimated that ** percent of Belgians suffered from a form of depressive disorder and ** percent from an anxiety disorder. From a regional perspective, the use of antidepressants was higher in Wallonia, and below the national average in Flanders. Unsurprisingly, the prevalence of depressive disorders was at its highest in Wallonia and at its lowest in Flanders.

Sleeping pills and tranquilizers 

Antidepressants are prescribed for various other conditions and are not usually indicated for mild depression, while the pharmaceutical treatment for anxiety disorders is generally sleeping pills and tranquilizers. For instance, over ** percent of Belgians used sleeping pills and tranquilizers in 2018. In the country, such drugs can be prescribed by general practitioners and most commonly by psychiatrists. In 2017, the number of active psychiatrists in Belgium notably amounted to over *** thousand professionals.

From 2001 to 2020, the prevalence of depressive disorders increased in the Belgian population. In 2020, it was estimated that ** percent of the Belgian population had a form of depressive disorder. Depression and anxiety were the most common mental health issues in the country. Although the prevalence of such disorders seemed to decrease significantly in 2018, this could be the result of a methodological break. Indeed, *** different scales were used to evaluate depressive disorders in respondents. From 2001 to 2013, the Symptom Checklist (SCL-90r) was used, whereas the Patient Health Questionnaire (PHQ) was used in 2018 and 2020. Regional prevalence of depression and antidepressant consumption  From a regional perspective, Wallonia faced the highest prevalence of depressive disorders, whilst the prevalence was at its lowest in Flanders. In 2018, an estimated *** percent of the Belgian population were taking antidepressants. Similarly, the regional use of antidepressants was higher in Wallonia than in the other regions. However, it is important to state that such medication can be prescribed for other afflictions than depression. Ultimately, the use of antidepressants was on the rise in Belgium. Impact of the coronavirus on mental health  Social restrictions due to the coronavirus are bound to have negatively impacted mental health. The high prevalence of depressive disorders is to be considered in the context of the Coronavirus (COVID-19) pandemic. Indeed, the 2020 figure has been calculated early in the year, during the confinement of the Belgian population. Furthermore, as any scale evaluating psychological problems, a margin of error is to be considered. Nonetheless, these numbers give useful insight into the landscape of mental health in Belgium.

Across the selected European countries Portugal had the highest share of spending on antidepressant drugs (AD) on the total pharmaceutical sales in 2022 (or latest year available: 2021), accounting for **** percent. Spain and Iceland followed, with *** and *** percent, respectively. This statistics depicts the share of AD spending on the total pharmaceutical sales in selected European countries in 2022.